Postmenopausal women w/ history of stroke or other significant risk factors eg, transient ischemic attack or atrial fibrillation. History of oral estrogen-induced hypertriglyceridemia. Discontinue use in case of illness or 3 days prior immobilisation occurs. Breast cancer. Closely monitor serum total bilirubin, γ-glutamyl transferase, alkaline phosphatase, ALT & AST. Monitor serum triglycerides during therapy. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Concomitant use w/ systemic estrogen. Mild & moderate renal impairment. Not to be used in hepatic & severe renal impairment. Pregnancy. Not recommended during lactation. May affect the development of the baby. Childn.
Sign Out
